Having pulmonary renal syndrome (PRS), a potentially life-threatening condition marked by lung and kidney problems, is associated with a higher…
Lila Levinson, PhD
Lila is a Science Writer at BioNews. She completed her PhD in neuroscience at the University of Washington, where she studied how the natural flexibility of the human brain can be used to promote recovery after injury. Previously, she has written about science for The Dallas Morning News and the University of Washington Computational Neuroscience Center. She enjoys exploring the Pacific Northwest and spending time with her cat, Fibonacci.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Lila Levinson, PhD
The most common types of ANCA-associated vasculitis (AAV) show distinctive activity patterns of type I interferons (IFN-I), a…
A combination of rituximab (sold as Rituxan and biosimilars) and low-dose glucocorticoids may safely stabilize interstitial lung disease (ILD)…
Tavneos (avacopan) plus a short course of glucocorticoids is as effective as glucocorticoids alone for treating rapidly progressive glomerulonephritis…
Four proteins in the kidneys likely contribute to the development of ANCA-associated vasculitis (AAV), and may be used as…
A low-dose course of glucocorticoid therapy results in similar outcomes as a higher-dose option in people with ANCA-associated vasculitis…
Combining two diagnostic systems used to classify cases of ANCA-associated vasculitis (AAV) in adults improved classification performance in a…
Alivedx’s Mosaiq Aiplex vasculitis assay, a platform test for the two main self-reactive antibodies that drive most cases of…
In ANCA-associated vasculitis (AAV), the involvement of the central nervous system (CNS), that is, the brain and spinal cord,…
Note: This story was updated on Aug. 6, 2025, to correct that proteinase 3 (PR3) and myeloperoxidase (MPO) are the…